There were three objectives to the present study: (1) compare the bladder infection rate and extent of biofilm formation for seven untreated spinal cord injured (SCI) patients and seven given prophylactic co-trimoxazole, (2) identify a level of bacterial adhesion to bladder cells which could be used to help predict symptomatic infection, and (3) determine from in vivo and in vitro studies whether fluoroquinolones were effective at penetrating bacterial biofilms. The results showed that the infection rate had not changed with the introduction of prophylaxis. However, the uropathogenic population had altered subsequent to the introduction of prophylaxis with E. coli being replaced by E. faecalis as the most common cause of infection. In 63% of the specimens from asymptomatic patients, the bacterial counts per cell were < 20, while 81% of specimens from patients with at least one sign and one symptom of urinary tract infection (UTI) had > 20 adherent bacteria per bladder cell. Therefore, it is proposed that counts of > 20 bacteria adherent to sediment transitional epithelial bladder cells may be predictive of symptomatic UTI. Clinical data showed that fluoroquino lone therapy reduced the adhesion counts to < 20 per cell in 63% of cases, while trimethoprim-sulfamethoxazole only did so in 44%. Further in vitro testing showed that ciprofloxacin (0.1, 0.5 and 1.0,Ltg/ml) partially or completely eradicated adherent biofilms from 92% of spinal cord injured patients' bladder cells, while ofloxacin did so in 71 % cases and norfloxacin in 56%. These findings have important implications for the detection and treatment of bac teriuria in spinal cord injured patients.
Introduction
Symptomatic urinary tract infection (UTI) still remains a potentially life-threatening disease in spinal cord injured (SCI) patients and those with neurogenic bladder disturb ances. 1 The issue of whether or not to treat UTI and asymptomatic bacteriuria (ABU) in these patients has recently been raised2 and recommendation made that asympto matic bacteriuria should not be treated. However, this recommendation was made without the knowledge that adherent bac terial biofilms exist on bladder cells and devices whether or not antibiotics are administered3.4,5 and the presence of these biofilms correlates with a significant loss in bladder cell viability. 4 The use of prophy laxis, primarily with cotrimoxazole, is con sidered an effective method to prevent full blown bladder infection in otherwise healthy premenopausal women, 6 However, its role as a prophylactic agent in SCI patients is less clear.
The present study was undertaken to address three questions: (1) Does prophy lactic management with co-trimoxazole lower bladder infection rates and eradicate adherent biofilms in SCI patients? (2) Does the number of adherent bacteria indicate whether or not a symptomatic infection will arise? (3) Are fluoroquinolones effective at penetrating and eradicating adherent bio films? The latter question arises from in vitro and in vivo observations that of the many antimicrobial agents used to prevent and treat biofilm related infections, only ciprofloxacin, a potent fluoroquinolone, has shown good activity to dateS,7,8 (Preston CAK et al, unpublished),
Materials and methods

Patients
Fourteen SCI patients, aged 20-66 years (three females, 11 males), undergoing a hospital rehabilitation program provided written consent to participate in the study, approved by Parkwood Hospital and the University of Western Ontario Health Review Board, In all cases, bladder man agement comprised intermittent catheter ization, Each patient provided urine samples for S weeks, The urine specimens were cultured using standard microbiology laboratory techniques, and sediment transitional cells were Gram stained and the number of adherent organisms enumerated on 50 cells, In addition, cells from each sample were sonicated to remove adherent bacteria, and these organisms were then inoculated onto blood and brain heart infusion agar plates to determine the numbers of viable bacteria which had been attached to the cells.
The patients were monitored for signs and symptoms of UTI, namely spasticity, fever, cloudy and foul odour urine. Seven patients did not receive prophylactic therapy and seven were given daily co-trimoxazole (160 mg trimethoprim, SOO mg sulfamethoxazole). Symptomatic UTI was actively treated with an agent to which the infecting bacteria was sensitive: namely, ciprofloxacin (500 mg b. i. In vitro incubation of epithelial cells with antibiotics In order to determine if fluoroquinolones were able to kill adherent bacteria on the patients' epithelial cells, three concentra tions (0. 1, 0. 5, 1.0,ug/ml) of ciprofloxacin, ofloxacin and norfloxacin were incubated with 105 cells in 1 ml buffer for 24 hours at 37°C. The cells were then sonicated to remove adherent bacteria, and these were then washed and quantitated by culture on agar. The percentage reduction compared to untreated controls was calculated.
Scanning electron microscopy A previous study3 had illustrated the pres ence of biofilms on bladder cells of SCI patients. In the latest study, several samples were processed for scanning electron micro scopy to confirm these findings. A photo micrograph is included in Figure 1 , not only for this purpose but also to illustrate the clumping of the organisms and the appear ance of a conditioning film over the biofilm.
Results
The seven patients who had no antibiotic prophylaxis had an infection rate per sample of 68%, which was not statistically higher than the 54% infection rate for the seven patients given prophylactic co-trimoxazole. However, as shown in Table I , the uro pathogens isolated were quite different in each group, with E. coli being replaced by E. faecalis as the dominant pathogen upon use of co-trimoxazole.
An examination of the numbers of bac teria adherent per bladder cell showed a mean of 44 ± SD49 in 27 samples from the untreated patients, which was not statistic ally different from the mean of 39 ± 42 per cell from 26 samples from patients given co-trimoxazole prophylactically.
Sixteen specimens were able to be pro cessed by sonication. There was no correla tion between the number of adherent bac teria counted on cells by light microscopy and those found by sonication and quanti tative culture (Fig 2) . However, 11 of 16 (69%) samples with mean adhesion counts < 20 per cell had no bacteria recovered after sonication, whereas viable bacteria were recovered from all samples with means > 20 per cell.
A combined analysis of bacterial adhesion counts from patients without signs or symp toms of UTI showed that in 19 of 30 (63%) Mean adherent bacteria cell specimens, the mean count was < 20 per cell. In 26 of 32 specimens (81%) where patients had at least one sign and one symptom of UTI, the adhesion counts were > 20 per cell. Cloudy and foul odour urine per se would not be indicative of sympto matic infection and thus another symptom had to be recorded, such as spasticity, plus confirmation by culture of > 105 organisms per ml urine. A further examination of bladder cells from patients actively treated with cipro floxacin and norfloxacin showed a mean of < 20 bacteria per cell in five of eight samples (63%), compared to 14 of 32 (44%) when the patients were given co-trimox azole.
All the isolated organisms tested for antibiotic penetration in vitro were sensitive to the fluoroquinolones, except one strain of E. faecalis. In vitro incubation of cells with adherent bacteria and the three fluoro quinolones showed that all three agents were equally effective at killing the adherent organisms ( Table II) . The increased eradi cation of bacteria at higher concentrations was not linear. The eradication of the adherent bacteria was partial or complete in 92% of the ciprofloxacin treated specimens, 71 % of the ofloxacin (one sample was lost) and 56% of the norfloxacin specimens. 
Discussion
The findings of the present study verified the presence of viable, and often dense, bacterial biofilms adherent to the transi tional epithelial cells of SCI patients. The biofilms were often seen by microscopy to be embedded within a conditioning film (Fig 1) . Although only 14 patients were examined, there was no evidence to indicate that the UTI rate had decreased with the use of prophylactic co-trimoxazole. A study of 81 patients is now underway to determine more conclusively whether prophylactic therapy altered the infection rate and to what extent it impacted upon uropathogen strain, patient wellbeing and cost. In the present study, there was strong evidence to indicate that E. faecalis had replaced E. coli as the major cause of UTI following the introduction of prophylaxis. A previous Japanese study of patients with complicated UTI (underlying neurogenic bladder dys function and cancer) has shown a high incidence of enterococcal infection and drug resistance to many antimicrobial agents, including co-trimoxazole (57% ) .9 Of the few cases treated with ciprofloxacin, norflox acin, enoxacin and ofloxacin, good eradica tion rates were found with few cases of recurrence. This compares favourably with the findings of the present study where in vitro fluoroquinolone concentrations were 100-1000-fold lower than those present in the bladder of patients treated with these 
an ti biotics.
One of the major problems in the man agement of SCI patients is predicting when the asymptomatic bacteriuria will go on to cause symptomatic infection and morbidity. The data obtained in the present study indicated that signs and symptoms of UTI were associated with mean bacterial adhe sion counts of over 20 organisms per cell. Clearly, these data alone are not sufficient to influence clinical decision making and larger numbers of SCI patients and other patient groups must be tested to confirm the observation. The key will be to produce a diagnostic assay which is sufficiently sensi tive and specific to put these in vitro findings into practice. By providing a physician with information on the nature and extent of bladder cell colonization, it should be feas ible to better decide if antibiotic therapy is required.
An examination of the bacterial adhesion counts showed that there was some correla tion between the ability of more adhesive (and perhaps more virulent) uropathogens to cause symptomatic UTI, in agreement with in vitro results for E. coli.1O In cases where there was no correlation between adhesion per cell and numbers of bacteria recovered from sonicated cells (Fig 2) , there could be several explanations. (1) A number of the adherent bacteria may have been killed by antibiotics, but still have re mained attached. (2) The light microscopy technique may have underestimated the numbers of adherent bacteria, especially cocci which, as Figure 1 shows, can be present in small microcolonies.
The potential of fluoroquinolones, espe cially ciprofloxacin, to penetrate adherent biofilms appears to have some merit, based upon in vitro studies.7•s In the present study, ciprofloxacin and norfloxacin therapy re duced the adhesion counts to < 20 per cell in 63% of cases and co-trimoxazole only did so in 44 % . Admittedly, this difference could be due to relative activity of the antibiotics rather than ability to penetrate biofilms. However, further in vitro studies confirmed the potency of three fluoroquinolones at killing adherent bacteria on the epithelial cells, and showed that low doses had a partial effect. These findings do not neces sarily mean that fluoroquinolones should be used prophylactically or as the drug of choice to treat UTI in SCI patients. Cer tainly, there are arguments for using less expensive products such as co-trimoxazole, which at our institution costs around 10 cents per tablet compared to having to use active therapy to clear an infection, for example using 400 mg norfloxacin q12 h at $2 per tablet or 500 mg q12 h ciprofloxacin at $2. 60 per tablet. However, unless an References Paraplegia 32 (1994) [468] [469] [470] [471] [472] antibiotic is able to penetrate and/or eradi cate bacterial biofilms, its effectiveness is questionable (except that it may prevent spread of planktonic E. Coli to the kidney) and its usage could result in the emergence of more problematic pathogens.
Clinical trials will be required to verify that ciprofloxacin and other fluoroquino lones can truly eradicate biofilms and pro vide a clinically significant endpoint. Further studies would also be useful with shorter courses (which have been effective in otherwise healthy adults)l1 or even sub minimum inhibitory concentrations of cipro floxacin, to reduce adhesion and temporar ily prevent recurrence of infection, without giving rise to a significant increase in the number of drug resistant uropathogens.
